|
RBAK expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.16637818795107E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.45639097740514E-12 |
| Normal-vs-Stage2 |
1.09499999956242E-07 |
| Normal-vs-Stage3 |
1.98585592414702E-12 |
| Normal-vs-Stage4 |
6.87672141452822E-13 |
| Stage1-vs-Stage2 |
1.381560E-01 |
| Stage1-vs-Stage3 |
1.398430E-01 |
| Stage1-vs-Stage4 |
1.013180E-01 |
| Stage2-vs-Stage3 |
2.998100E-02 |
| Stage2-vs-Stage4 |
2.189700E-02 |
| Stage3-vs-Stage4 |
6.675200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.64546154479694E-12 |
| Normal-vs-AfricanAmerican |
1.33089999998504E-06 |
| Normal-vs-Asian |
3.06800029825638E-10 |
| Caucasian-vs-AfricanAmerican |
7.102200E-01 |
| Caucasian-vs-Asian |
6.160400E-01 |
| AfricanAmerican-vs-Asian |
9.990200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.91540117100431E-11 |
| Normal-vs-Female |
3.06266123573096E-12 |
| Male-vs-Female |
4.391400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74893433069201E-12 |
| Normal-vs-Age(41-60Yrs) |
4.61652938099633E-12 |
| Normal-vs-Age(61-80Yrs) |
5.6383009372496E-11 |
| Normal-vs-Age(81-100Yrs) |
2.223400E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.611000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.447400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.266600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.539200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.213000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.808800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.405860E-04 |
| Classical-VS-Follicular |
5.129600E-01 |
| Classical-VS-Other |
5.306400E-01 |
| Classical-VS-Normal |
6.20139495310923E-11 |
| Tall-VS-Follicular |
2.631200E-04 |
| Tall-VS-Other |
2.648600E-01 |
| Tall-VS-Normal |
1.63591362678517E-12 |
| Follicular-VS-Other |
4.494200E-01 |
| Follicular-VS-Normal |
1.74680003794947E-09 |
| Other-VS-Normal |
1.123790E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.44613268213834E-12 |
| Normal-vs-N1 |
2.47202258663037E-12 |
| N0-vs-N1 |
2.190200E-01 |
|
|
